Retina Implants Help Blind To See
Noteworthy news from medtech start-ups. This month we profile three emerging artificial retina developers: Nano Retina, 2C Tech Corp. and LambdaVision.
You may also be interested in...
On many fronts, 2011 was an event-filled year for the retinal disease market, beginning with the publication of the CATT trial comparing off-label intravitreal Avastin versus Lucentis for the treatment of AMD, and ending with several important milestones for device manufacturers operating in this space. But while the retinal device field is making progress in many areas, companies continue to struggle to meet shifting FDA approval requirements.
After decades without an approval pathway for excipients, FDA pilot program paves the way for innovation.